{
"id":"mk19_b_en_s3",
"subspecialtyId":"en",
"title":"Disorders of the Adrenal Glands",
"jsonContent":{
"type":"section",
"id":"mk19_b_en_s3",
"title":{
"__html":"Disorders of the Adrenal Glands"
},
"titleNode":{
"type":"section-title",
"hlId":"ce2203",
"children":[
"Disorders of the Adrenal Glands"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_en_s3_1",
"title":{
"__html":"Adrenal Anatomy and Physiology"
},
"titleNode":{
"type":"section-title",
"hlId":"69bcab",
"children":[
"Adrenal Anatomy and Physiology"
]
},
"children":[
{
"type":"p",
"hlId":"5910ad",
"children":[
"The adrenal glands have two functionally distinct regions: an outer cortex and an inner medulla. The adrenal cortex comprises three zones: the zona glomerulosa, zona fasciculata, and zona reticularis. The zona glomerulosa produces aldosterone under the regulation of the renin-angiotensin system. Major stimuli to aldosterone secretion include hypotension, hypovolemia, and hyperkalemia; adrenocorticotropic hormone (ACTH) is a less potent stimulus of aldosterone release. Aldosterone promotes sodium reabsorption and potassium excretion and the resultant expansion of extracellular volume increases blood pressure. Aldosterone also has direct inflammatory and fibrotic effects on other organs that are independent of its blood pressure effects."
]
},
{
"type":"p",
"hlId":"c319d5",
"children":[
"Cortisol production in the zona fasciculata is regulated by pituitary ACTH release. Cortisol exhibits a distinct diurnal rhythm characterized by peak levels on awakening, decreasing to very low levels by evening. Most cortisol circulates in the blood attached to cortisol-binding protein, with only a small fraction circulating as biologically active, free hormone. Cortisol levels increase in response to physical illness and psychological stress. Cortisol actions include immune, vascular, anti-inflammatory, and metabolic effects."
]
},
{
"type":"p",
"hlId":"1c5e79",
"children":[
"Dehydroepiandrosterone (DHEA) and its sulfate are weak androgens produced in the zona reticularis and peripherally converted to testosterone. In women, the adrenal gland is a significant contributor to circulating androgen levels, and testicular production of androgens is the primary source in men."
]
},
{
"type":"p",
"hlId":"608c8f",
"children":[
"The adrenal medulla secretes norepinephrine and epinephrine in response to hypotension, hypoglycemia, fear, acute illness, and other causes of psychological and physical stress. Catecholamines interact with α- and β-adrenergic receptors to increase pulse and blood pressure, dilate bronchioles, and increase metabolic rate. A small fraction of norepinephrine and epinephrine is excreted in the urine as free hormone; the rest is degraded in the liver to metanephrine and normetanephrine before urinary excretion."
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s3_2",
"title":{
"__html":"Adrenal Hormone Excess"
},
"titleNode":{
"type":"section-title",
"hlId":"8adfc4",
"children":[
"Adrenal Hormone Excess"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_en_s3_2_1",
"title":{
"__html":"Cortisol Excess (Cushing Syndrome Caused by Adrenal Mass)"
},
"titleNode":{
"type":"section-title",
"hlId":"6e24c9",
"children":[
"Cortisol Excess (Cushing Syndrome Caused by Adrenal Mass)"
]
},
"children":[
{
"type":"p",
"hlId":"5d530c",
"children":[
"The most common cause of hypercortisolemia is exogenous ingestion of glucocorticoids. Pituitary adenoma production of ACTH is the most common cause of Cushing syndrome (see ",
{
"type":"cross-reference",
"target":"mk19_b_en_s2_2_1",
"children":[
"Disorders of the Pituitary Gland"
]
},
"). Cortisol-secreting adrenal adenomas and, rarely, carcinomas account for 15% to 20% of endogenous causes of Cushing syndrome. Excess cortisol secretion from these tumors suppresses pituitary ACTH production (ACTH-independent). Although many of the symptoms and signs of Cushing syndrome are common in the general population, some, including supraclavicular fat pads, proximal muscle weakness, facial plethora, and wide (>1 cm) violaceous striae ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_en_f04",
"wrapId":"1",
"children":[
"Figure 4"
]
}
]
},
")"
]
},
", are more specific to Cushing syndrome. Evaluation for Cushing syndrome should be limited to patients with a significant clinical suspicion of disease, including specific signs of Cushing syndrome or an adrenal mass."
]
},
{
"type":"inline-wrap",
"wrapId":"1",
"contentIds":[
"mk19_b_en_f04"
]
},
{
"type":"p",
"hlId":"a591ff",
"children":[
"The evaluation of Cushing syndrome involves initial and confirmatory testing for the presence of nonphysiologic cortisol excess. Steps after confirmation are (1) determining Cushing syndrome as ACTH independent or dependent and (2) localizing the source of ACTH in ACTH-dependent disease or confirming the presence of adrenal mass (or masses) in ACTH-independent disease."
]
},
{
"type":"p",
"hlId":"02361f",
"children":[
"The diagnosis of Cushing syndrome necessitates a combination and repetition of tests ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_en_f05",
"wrapId":"2",
"children":[
"Figure 5"
]
}
]
},
")"
]
},
". Measurement of morning or random serum cortisol is unreliable because of overlap of serum cortisol levels in Cushing syndrome with normal levels and those seen with mild hypercortisolism or pseudo-Cushing state in the absence of Cushing syndrome. In addition, total cortisol levels are unreliable in the presence of abnormal binding proteins, such as in acute illness, liver dysfunction, low protein states, and administration of oral estrogens."
]
},
{
"type":"inline-wrap",
"wrapId":"2",
"contentIds":[
"mk19_b_en_f05"
]
},
{
"type":"p",
"hlId":"2178ae",
"children":[
"Three initial tests for Cushing syndrome have similar diagnostic accuracy: the 24-hour urine free cortisol, serial late-night salivary cortisol, and overnight low-dose (1-mg) dexamethasone suppression (LDST) tests. Urine free cortisol and late-night salivary cortisol reflect serum free cortisol fraction and avoid the challenges of interpretating changes in cortisol-binding proteins that may occur with the LDST."
]
},
{
"type":"p",
"hlId":"8cdda0",
"children":[
"Urine free cortisol requires a 24-hour urine collection. Spurious elevation of urine free cortisol can result from physiologic hypercortisolemia or when significant polyuria (>5 L/d) is present. False-negative results can occur in advanced kidney disease or in patients with variable rates of cortisol secretion."
]
},
{
"type":"p",
"hlId":"a4df38",
"children":[
"Late-night salivary cortisol is collected at home by the patient between 11 ",
{
"type":"tag",
"tagName":"small",
"attrs":{
},
"children":[
"PM"
]
},
" and midnight on at least two different nights. Elevated levels suggest the loss of normal cortisol diurnal rhythm seen in Cushing syndrome. This test is not recommended in patients who do shift work, have an inconsistent sleep pattern, or have gingivitis. Recent cigarette smoking or contamination by topical glucocorticoids can cause false-positive results."
]
},
{
"type":"p",
"hlId":"fc02f1",
"children":[
"The LDST depends on the principle that autonomous cortisol secretion is not suppressed by exogenous glucocorticoids. Dexamethasone is given at 11 ",
{
"type":"tag",
"tagName":"small",
"attrs":{
},
"children":[
"PM"
]
},
" and serum total cortisol is measured at 8 ",
{
"type":"tag",
"tagName":"small",
"attrs":{
},
"children":[
"AM"
]
},
" the following morning. A post-dexamethasone cortisol level of greater than 1.8 μg/dL (49.7 nmol/L) is considered a positive result. False-positive results may occur with concomitant use of medications (carbamazepine, phenytoin, pioglitazone) that induce hepatic cytochrome P-450 3A4 enzymes and accelerate dexamethasone metabolism. Simultaneous measurement of serum dexamethasone can confirm patient adherence or altered dexamethasone metabolism."
]
},
{
"type":"p",
"hlId":"a881e5",
"children":[
"The clinical probability of Cushing syndrome should guide the testing strategy. If the index of suspicion for Cushing syndrome is low, a single negative test makes Cushing syndrome unlikely. If suspicion is high, two different negative initial tests are recommended to rule out disease. Similarly, many factors can raise cortisol levels in the absence of Cushing syndrome; positive test interpretation should incorporate the clinical probability of disease. A urine free cortisol level greater than three times the upper normal range in the setting of clinical manifestations of Cushing syndrome is highly suggestive of the diagnosis, whereas a positive test in the setting of low suspicion does not support the diagnosis alone and requires further testing. If two of three initial screening tests are positive, further evaluation should involve consultation with an endocrinologist."
]
},
{
"type":"p",
"hlId":"358131",
"children":[
"When the diagnosis of Cushing syndrome is established, the next step is measurement of ACTH; if suppressed (<5 pg/mL [1.1 pmol/L]), an ACTH-independent cause is likely and dedicated adrenal CT or MRI is indicated. If adrenal glands appear normal on imaging, the diagnosis of Cushing syndrome should be questioned."
]
},
{
"type":"p",
"hlId":"87412d",
"children":[
"Surgical resection is the definitive treatment for benign and malignant cortisol-secreting adrenal tumors. Following adrenalectomy, patients require daily glucocorticoid therapy to allow the contralateral adrenal gland to recover from prolonged ACTH suppression. Recovery of adrenal function may take several years depending on the severity of disease (see ",
{
"type":"cross-reference",
"target":"mk19_b_en_s2_2_1",
"children":[
"Disorders of the Pituitary Gland"
]
},
")."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"483165",
"children":[
"Initial tests for Cushing syndrome have similar diagnostic accuracy and are measurement of 24-hour urine free cortisol, the serial late-night salivary cortisol test, and the overnight low-dose (1-mg) dexamethasone suppression test."
]
},
{
"type":"keypoint",
"hlId":"a23f82",
"hvc":true,
"children":[
"Evaluation for Cushing syndrome should be limited to patients with a significant clinical suspicion of disease, including specific signs of Cushing syndrome or an adrenal mass."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s3_2_2",
"title":{
"__html":"Primary Aldosteronism"
},
"titleNode":{
"type":"section-title",
"hlId":"052f1d",
"children":[
"Primary Aldosteronism"
]
},
"children":[
{
"type":"p",
"hlId":"9be206",
"children":[
"Primary aldosteronism is a common cause of secondary hypertension. Traditionally, hypokalemia was considered a prerequisite for diagnosis, but it is now recognized that most patients have normal potassium levels. Identification of patients with primary aldosteronism is important because aldosterone has deleterious effects on the cardiovascular system; treatment can prevent progression and can sometimes reverse changes. Higher cardiovascular morbidity and mortality have been noted in patients with primary aldosteronism compared with those with primary hypertension and similar blood pressure control. Guidelines on testing for primary aldosteronism are provided in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t25",
"wrapId":"3",
"children":[
"Table 25"
]
}
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"3",
"contentIds":[
"mk19_b_en_t25"
]
},
{
"type":"p",
"hlId":"79b72a",
"children":[
"Primary aldosteronism is caused by hyperplasia of both adrenal glands (idiopathic hyperaldosteronism) in approximately 60% of cases. A unilateral aldosterone-producing adenoma (APA) is found in approximately 35% of cases. The diagnosis of primary aldosteronism involves performing stepwise case detection followed by confirmatory testing and localization studies. The most reliable case-detection test is calculation of a plasma aldosterone concentration/plasma renin activity (PAC/PRA) by measuring PAC and PRA (or direct renin concentration) in a midmorning seated sample. A PAC/PRA greater than 20 with a PAC of at least 15 ng/dL (414 pmol/L) is considered a positive result and should prompt referral to an endocrinologist; additional confirmatory testing may be necessary."
]
},
{
"type":"p",
"hlId":"1bdaa8",
"children":[
"Multiple medications may affect results. In patients taking an ACE inhibitor or an angiotensin receptor blocker, renin should be elevated and testing may start with PRA measurement. If the PRA is suppressed, the likelihood of primary aldosteronism is high and a PAC/PRA should be performed; a non-suppressed plasma renin level rules out mineralocorticoid excess. Mineralocorticoid receptor antagonists (spironolactone and eplerenone) and high doses of amiloride can significantly interfere with interpretation of PAC/PRA and should be discontinued 4 to 6 weeks before evaluation if possible. However, if testing while a patient is taking a mineralocorticoid receptor antagonist reveals suppressed PRA, further testing can be done without stopping the medication."
]
},
{
"type":"p",
"hlId":"67ce99",
"children":[
"Other antihypertensive agents may have minor effects on aldosterone and renin levels and impact PAC/PRA interpretation ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t26",
"wrapId":"4",
"children":[
"Table 26"
]
}
]
},
")"
]
},
". Hydralazine and slow-release verapamil have minimal effects on aldosterone and renin secretion and can be substituted for other agents if the PAC/PRA is equivocal."
]
},
{
"type":"inline-wrap",
"wrapId":"4",
"contentIds":[
"mk19_b_en_t26"
]
},
{
"type":"p",
"hlId":"1f14e7",
"children":[
"The localization study of choice for primary aldosteronism is a dedicated adrenal CT. Findings may include normal adrenal glands, unilateral or bilateral adenoma(s), or hyperplasia. However, the inability of CT to visualize smaller APAs and the frequent presence of non-functioning incidental adrenal masses limits its use. Most patients with primary aldosteronism should undergo adrenal vein sampling to confirm the source."
]
},
{
"type":"p",
"hlId":"f67db6",
"children":[
"Medical therapy with an aldosterone receptor antagonist (spironolactone or eplerenone) is the treatment of choice for primary aldosteronism caused by idiopathic hyperaldosteronism and in patients with APA who are not candidates for or refuse surgery. Spironolactone is often preferred over eplerenone because it is less expensive and more potent. However, spironolactone is more likely to cause dose-dependent adverse effects of gynecomastia and erectile dysfunction in men and menstrual irregularities in women. Hypokalemia almost always resolves with treatment, but blood pressure control may require additional agents. No studies clearly show superiority of adrenalectomy compared with medical therapy for APA, but surgery may be more cost-effective in the long term."
]
},
{
"type":"p",
"hlId":"a1161d",
"children":[
"Laparoscopic adrenalectomy is effective for unilateral disease and reduces plasma aldosterone and its attendant increased risk of cardiovascular disease. Hypertension is improved in most patients and cured in some. Patients are more likely to achieve resolution of hypertension if they are taking fewer than three antihypertensive agents preoperatively, and if they have one or no first-degree relatives with hypertension. Serum potassium levels should be monitored weekly for the first month postoperatively. Patients should be instructed to eat a sodium-rich diet to avoid the risk of hyperkalemia from transient reduction in aldosterone production in the remaining adrenal gland because of chronic suppression of the renin-angiotensin system by the hyperaldosteronism."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"1e8d56",
"children":[
"The most reliable case-detection test for primary aldosteronism is calculation of a plasma aldosterone–plasma renin ratio in a midmorning seated sample."
]
},
{
"type":"keypoint",
"hlId":"5f5d3f",
"hvc":true,
"children":[
"In patients taking an ACE inhibitor or an angiotensin receptor blocker, a simple initial test for primary aldosteronism is a plasma renin activity measurement; a non-suppressed plasma renin level rules out mineralocorticoid excess."
]
},
{
"type":"keypoint",
"hlId":"18b965",
"children":[
"Medical therapy with an aldosterone receptor antagonist is the treatment of choice for idiopathic hyperaldosteronism and in patients with aldosterone-producing adenoma who refuse or are not candidates for surgery."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s3_2_3",
"title":{
"__html":"Pheochromocytoma and Paraganglioma"
},
"titleNode":{
"type":"section-title",
"hlId":"060860",
"children":[
"Pheochromocytoma and Paraganglioma"
]
},
"children":[
{
"type":"p",
"hlId":"317482",
"children":[
"Pheochromocytomas and paragangliomas are catecholamine-secreting tumors that arise from chromaffin cells of the adrenal medulla (80%) and extra-adrenal (mostly abdominal) sympathetic ganglia, respectively. Tumors can also arise from parasympathetic ganglia in the head and neck, but these are rarely secretory."
]
},
{
"type":"p",
"hlId":"ffe491",
"children":[
"Hypertension associated with pheochromocytoma and paraganglioma can show a sustained pattern, with or without paroxysms, or occur as paroxysms only. Some patients remain normotensive. Fewer than 50% of patients have the classic triad of palpitations, headache, and diaphoresis."
]
},
{
"type":"p",
"hlId":"dafc98",
"children":[
"Indications for testing for pheochromocytoma are shown in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t25",
"wrapId":"5",
"children":[
"Table 25"
]
}
]
},
". Initial tests include measurement of plasma free metanephrine collected in a supine position or 24-hour urine fractionated metanephrine and catecholamine levels. The presence of psychological or physical stress and medications can affect results ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t27",
"wrapId":"5",
"children":[
"Table 27"
]
}
]
},
")"
]
},
"; medications should be discontinued at least 2 weeks before testing if possible. Interpretation of results must consider the extent of metanephrine elevation, and mild elevations may require repeat testing. Levels more than four times the upper limit of normal, in the absence of acute stress or illness, are consistent with a catecholamine-secreting tumor. The plasma-free metanephrine is highly sensitive (96% to 100%) with specificity of 85% to 89%. Urine fractionated metanephrine and catecholamines have higher specificity (98%) and sensitivity (up to 97%). Plasma free-metanephrine is a more convenient test and is often chosen if the index of suspicion is high. If suspicion is low, urine fractionated metanephrine and catecholamines may be a better option. The clinical relevance of significantly elevated metanephrine levels in hospitalized patients is uncertain and testing should be confirmed in the outpatient setting."
]
},
{
"type":"inline-wrap",
"wrapId":"5",
"contentIds":[
"mk19_b_en_t25",
"mk19_b_en_t27"
]
},
{
"type":"p",
"hlId":"734b19",
"children":[
"Attempts at tumor localization should only occur after establishing the biochemical diagnosis of catecholamine excess to avoid misdiagnosing an incidental nonfunctioning adrenal mass as a pheochromocytoma. The imaging modality of choice is an abdominal and pelvic contrast-enhanced CT because 85% of catecholamine-secreting tumors are intra-adrenal with 95% residing in the abdomen or pelvis. Typical imaging features of pheochromocytomas are shown in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t28",
"wrapId":"6",
"children":[
"Table 28"
]
}
]
},
". If the CT scan is negative, and suspicion of a catecholamine-secreting tumor is high, the next step is advanced imaging, including the iodine 123-metaiodobenzylguanidine, octreotide, or gallium-68 DOTATATE scans. Advanced imaging may also be indicated in patients with very large pheochromocytomas (>10 cm) to detect metastatic disease or paragangliomas to detect several tumors. Fludeoxyglucose-PET scan is more sensitive for detection of metastatic disease, but its use is generally reserved for those patients with established malignant tumors."
]
},
{
"type":"inline-wrap",
"wrapId":"6",
"contentIds":[
"mk19_b_en_t28"
]
},
{
"type":"p",
"hlId":"268344",
"children":[
"The definitive treatment for pheochromocytoma/paraganglioma is surgical resection. Preoperative α-receptor blockade with phenoxybenzamine for 10 to 14 days before surgery is essential to prevent hypertensive crises during surgery. The dose is progressively increased to achieve a blood pressure of 130/80 mm Hg or less and pulse of 60 to 70/min seated, and systolic pressure of 90 mm Hg or higher with pulse of 70 to 80/min standing. To facilitate dose escalation and mitigate the volume contraction effects of α-receptor blockade, patients are instructed to increase salt and fluid intake 3 days before surgery. A β-blocker is added after α-blockade is achieved to manage reflex tachycardia, but it should never be started before adequate α-blockade, because unopposed α-adrenergic vasoconstriction can result in a hypertensive crisis. As an alternative to phenoxybenzamine, selective α-1 receptor blockers such as doxazosin can be used off-label if availability, cost, or adverse effects, including hypotension, are a concern. Postoperatively, patients can have significant hypotension, and most require fluid and vasopressor support at least briefly."
]
},
{
"type":"p",
"hlId":"1e31bc",
"children":[
"Most pheochromocytomas/paragangliomas are benign. Pathologic findings do not predict which tumors will become malignant and develop metastases. Because metastases can occur decades after the initial diagnosis, patients should undergo long-term annual biochemical screening, typically with plasma-free metanephrine."
]
},
{
"type":"p",
"hlId":"c4157d",
"children":[
"At least one third of pheochromocytomas/paragangliomas are associated with a germline mutation. Pheochromocytomas may occur in familial syndromes including multiple endocrine neoplasia type 2, von Hippel-Lindau syndrome, and neurofibromatosis type 1 ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t29",
"wrapId":"7",
"children":[
"Table 29"
]
}
]
},
")"
]
},
". Therefore, all patients with catecholamine-secreting tumors should be offered genetic counseling."
]
},
{
"type":"inline-wrap",
"wrapId":"7",
"contentIds":[
"mk19_b_en_t29"
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"e16b4e",
"children":[
"Initial tests for pheochromocytoma include measurement of plasma free metanephrine levels or 24-hour urine fractionated metanephrine and catecholamine levels."
]
},
{
"type":"keypoint",
"hlId":"c0aff4",
"children":[
"Attempts at tumor localization should only occur after establishing the biochemical diagnosis of catecholamine excess to avoid misdiagnosing an incidental nonfunctioning adrenal mass as a pheochromocytoma."
]
},
{
"type":"keypoint",
"hlId":"6b278f",
"children":[
"The definitive treatment for pheochromocytoma/paraganglioma is surgical resection; preoperative α-blockade with phenoxybenzamine is essential to prevent hypertensive crises during surgery."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s3_2_4",
"title":{
"__html":"Androgen-Producing Adrenal Tumors"
},
"titleNode":{
"type":"section-title",
"hlId":"42725c",
"children":[
"Androgen-Producing Adrenal Tumors"
]
},
"children":[
{
"type":"p",
"hlId":"0d0013",
"children":[
"Androgen-producing adrenal tumors are rare and in women may lead to menstrual irregularities and virilization including hirsutism, voice-deepening, increased muscle mass, increased libido, and clitoromegaly. Androgen-secreting tumors of the adrenal gland are readily visible on CT imaging, and adrenal vein sampling to localize the tumor is rarely required. The treatment of choice is resection."
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s3_2_5",
"title":{
"__html":"Adrenocortical Carcinoma"
},
"titleNode":{
"type":"section-title",
"hlId":"024133",
"children":[
"Adrenocortical Carcinoma"
]
},
"children":[
{
"type":"p",
"hlId":"8ab62d",
"children":[
"Adrenocortical carcinoma (ACC) is a rare, aggressive tumor that often secretes excess hormones. Approximately 50% of ACCs secrete cortisol alone; approximately 20% to 30% secrete several hormones, including cortisol and androgens; and less than 10% secrete aldosterone alone. Patients may present with rapid onset of Cushing syndrome, with or without virilization, or symptoms from mass effect, such as increased abdominal girth and lower extremity edema. Disease is often at an advanced stage at the time of diagnosis, but some ACCs are discovered as an incidental adrenal mass (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t28",
"wrapId":"8",
"children":[
"Table 28"
]
}
]
},
")"
]
},
". For localized disease, first-line therapy includes open resection. Debulking surgery, radiation therapy, or chemotherapy may also be options for palliation in advanced ACC."
]
},
{
"type":"inline-wrap",
"wrapId":"8",
"contentIds":[
"mk19_b_en_t28"
]
},
{
"type":"p",
"hlId":"28ca4a",
"children":[
"Mitotane is an adrenolytic agent commonly used as adjuvant therapy and is associated with longer recurrence-free survival. Mitotane causes primary adrenal insufficiency (AI), and daily glucocorticoid replacement therapy is required, often in supraphysiologic doses, because of mitotane-induced accelerated metabolism of glucocorticoids; fludrocortisone replacement may also be required. Five-year survival rates range from 62% to 82% for those with disease confined to the adrenal gland and 13% for tumors associated with distant metastases."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"37a874",
"children":[
"Adrenocortical carcinoma is a rare, aggressive tumor that often secretes excess cortisol or androgen hormones; patients may present with rapid onset of Cushing syndrome with or without virilization or symptoms from mass effect."
]
},
{
"type":"keypoint",
"hlId":"5ed42c",
"children":[
"For localized adrenocortical carcinoma, first-line therapy includes open resection."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s3_3",
"title":{
"__html":"Adrenal Hormone Deficiency"
},
"titleNode":{
"type":"section-title",
"hlId":"b77586",
"children":[
"Adrenal Hormone Deficiency"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_en_s3_3_1",
"title":{
"__html":"Primary Adrenal Insufficiency"
},
"titleNode":{
"type":"section-title",
"hlId":"5deb8b",
"children":[
"Primary Adrenal Insufficiency"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_en_s3_3_1_1",
"title":{
"__html":"Causes and Clinical Features"
},
"titleNode":{
"type":"section-title",
"hlId":"f34535",
"children":[
"Causes and Clinical Features"
]
},
"children":[
{
"type":"p",
"hlId":"12709e",
"children":[
"The most common cause of primary AI is Addison disease, which is an autoimmune destruction of all layers of the adrenal cortex leading to progressive mineralocorticoid, glucocorticoid, and adrenal androgen deficiency. Approximately 90% of patients have 21-hydroxylase antibodies, and approximately 50% will develop another autoimmune endocrine disorder in their lifetime (primary hypothyroidism, primary ovarian insufficiency, hypoparathyroidism, or type 1 diabetes), which is termed “autoimmune polyglandular syndrome.” Celiac disease also occurs with increased frequency."
]
},
{
"type":"p",
"hlId":"fe5bd9",
"children":[
"Primary AI can also be caused by infection, infiltrative disorders such as sarcoidosis, and lymphoma. Metastatic disease involving the adrenals rarely leads to AI even if both adrenal glands are involved."
]
},
{
"type":"p",
"hlId":"ebda08",
"children":[
"Bilateral adrenal hemorrhage can present as acute AI and should be considered if unexpected hypotension develops. Risk factors include protein C deficiency, anticoagulation, disseminated intravascular coagulopathy, and sepsis."
]
},
{
"type":"p",
"hlId":"31d12e",
"children":[
"Primary AI is a life-threatening disorder that often presents with insidious onset of symptoms, making diagnosis a challenge ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t30",
"wrapId":"9",
"children":[
"Table 30"
]
}
]
},
")"
]
},
". It may also present as adrenal crisis, often precipitated by an acute illness or the initiation of thyroid hormone replacement in a patient with unrecognized chronic AI. ACTH levels are high because diminished adrenal cortisol production leads to decreased negative feedback to the hypophyseal-pituitary axis. Although not present in all patients, skin hyperpigmentation from stimulation of melanocytes by high levels of melanocyte-stimulating hormone (which has the same precursor molecule as ACTH) is considered a hallmark of primary AI."
]
},
{
"type":"inline-wrap",
"wrapId":"9",
"contentIds":[
"mk19_b_en_t30"
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s3_3_1_2",
"title":{
"__html":"Diagnosis"
},
"titleNode":{
"type":"section-title",
"hlId":"523223",
"children":[
"Diagnosis"
]
},
"children":[
{
"type":"p",
"hlId":"e01eb3",
"children":[
"Initial evaluation includes the measurement of 8 ",
{
"type":"tag",
"tagName":"small",
"attrs":{
},
"children":[
"AM"
]
},
" serum total cortisol and response to ACTH stimulation. An algorithm for the diagnosis of AI is outlined in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_en_f06",
"wrapId":"10",
"children":[
"Figure 6"
]
}
]
},
". Primary AI is confirmed by the combination of low serum cortisol and elevated serum ACTH levels. Additional evaluation may include assessment for autoimmune adrenalitis with measurement of 21-hydroxylase antibodies; CT of the adrenal glands may be necessary if antibodies are absent."
]
},
{
"type":"inline-wrap",
"wrapId":"10",
"contentIds":[
"mk19_b_en_f06"
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s3_3_1_3",
"title":{
"__html":"Treatment"
},
"titleNode":{
"type":"section-title",
"hlId":"4c4ac0",
"children":[
"Treatment"
]
},
"children":[
{
"type":"p",
"hlId":"6b3445",
"children":[
"Both glucocorticoid and mineralocorticoid therapy are required for treatment of primary AI. The preferred glucocorticoid is hydrocortisone taken two or three times daily. Adherence to several daily doses can be challenging, so once-daily prednisone can be used as an alternative ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t31",
"wrapId":"11",
"children":[
"Table 31"
]
}
]
},
")"
]
},
". The principle of replacement is to administer a higher dose in the morning and to avoid replacement in the evening. Despite this attempt to mimic diurnal variation, patients with primary AI report a decrease in health-related quality of life. Avoiding overreplacement with glucocorticoid is imperative to avoid the consequences of iatrogenic Cushing syndrome. Mineralocorticoid replacement is achieved with daily fludrocortisone."
]
},
{
"type":"inline-wrap",
"wrapId":"11",
"contentIds":[
"mk19_b_en_t31"
]
},
{
"type":"p",
"hlId":"952234",
"children":[
"Patients cannot mount an appropriate increase in cortisol with illness; therefore, instruction in “sick day” rules is essential to prevent adrenal crisis ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t32",
"wrapId":"12",
"children":[
"Table 32"
]
}
]
},
")"
]
},
". Patients should be counseled to wear a medical alert identification at all times, be prescribed an emergency kit that includes high-dose intramuscular steroids, and be counseled to seek medical attention if vomiting prevents taking steroid medications. Patients with untreated concomitant AI and hypothyroidism should always receive glucocorticoid replacement therapy first to prevent precipitation of adrenal crisis by thyroid hormone replacement."
]
},
{
"type":"inline-wrap",
"wrapId":"12",
"contentIds":[
"mk19_b_en_t32"
]
},
{
"type":"p",
"hlId":"5daf13",
"children":[
"“Adrenal fatigue” refers to a constellation of symptoms in patients who experience chronic emotional or physical stress that they attribute to the contradictory condition of simultaneous hyper- and hypocortisolism. No scientific evidence supports the existence of adrenal fatigue. Some patients labeled with “adrenal fatigue” are given glucocorticoid therapy or animal-derived adrenal gland extract that may contain active glucocorticoid, leading to exogenous suppression of ACTH production and iatrogenic Cushing syndrome. Sudden discontinuation of these products can lead to acute AI. Patients with these symptoms should be carefully tapered off any glucocorticoid therapy and other potential causes explored."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"8d533a",
"children":[
"The most common cause of primary adrenal insufficiency is autoimmune adrenalitis leading to progressive mineralocorticoid, glucocorticoid, and adrenal androgen deficiency."
]
},
{
"type":"keypoint",
"hlId":"7b382f",
"children":[
"Glucocorticoid and mineralocorticoid therapy are required for treatment of primary adrenal insufficiency."
]
},
{
"type":"keypoint",
"hlId":"65e30e",
"children":[
"Patients with adrenal insufficiency require instruction in “sick day” rules regarding glucocorticoid dosing to prevent adrenal crisis."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s3_3_2",
"title":{
"__html":"Adrenal Function During Serious Illness"
},
"titleNode":{
"type":"section-title",
"hlId":"8d0e5b",
"children":[
"Adrenal Function During Serious Illness"
]
},
"children":[
{
"type":"p",
"hlId":"ffa2a4",
"children":[
"During times of physiologic stress, the hypothalamic-pituitary-adrenal axis is stimulated to produce increased levels of cortisol. In some patients, the increase in cortisol secretion is thought to be suboptimal and termed “relative AI.” However, whether the entity of relative AI is a true disease is debated. Cortisol-binding globulin and albumin decrease in critical illness, lowering the measured total cortisol. No set of diagnostic criteria for relative AI has been agreed on, despite the ability to measure free cortisol, calculated free cortisol, and basal and ACTH-stimulated total cortisol level in critically ill patients. Studies do not show improved survival in patients with relative AI treated with high-dose glucocorticoid therapy. Shock reversal, however, may be improved; therefore, it is recommended that stress-dose hydrocortisone be administered to patients with shock that is resistant to standard fluid and vasopressor therapy."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s3_4",
"title":{
"__html":"Adrenal Mass"
},
"titleNode":{
"type":"section-title",
"hlId":"476021",
"children":[
"Adrenal Mass"
]
},
"children":[
{
"type":"p",
"hlId":"f9bae4",
"children":[
"An adrenal incidentaloma is an adrenal mass larger than 1 cm in diameter that is detected on imaging performed for purposes other than suspicion of adrenal disease ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_en_f07",
"wrapId":"13",
"children":[
"Figure 7"
]
}
]
},
")"
]
},
". The prevalence of adrenal incidentaloma increases with age and is approximately 10% in patients 70 years or older. Most lesions are benign, nonfunctioning adenomas, but approximately 10% to 15% secrete excess hormones. Other causes of adrenal masses are metastases (increased probability if known primary malignancy), myelolipoma, cysts, and adrenocortical carcinoma."
]
},
{
"type":"inline-wrap",
"wrapId":"13",
"contentIds":[
"mk19_b_en_f07"
]
},
{
"type":"p",
"hlId":"cde19f",
"children":[
"The finding of an incidental adrenal mass prompts two questions: (1) Is the mass secreting excess hormone (aldosterone, cortisol, or catecholamines)? and (2) Is the mass benign or malignant? All patients with an adrenal incidentaloma should undergo testing for Cushing syndrome and for pheochromocytoma if the unenhanced CT attenuation is greater than 10 HU. Patients with hypertension or with hypokalemia require testing for primary aldosteronism."
]
},
{
"type":"p",
"hlId":"f34ffd",
"children":[
"Although Cushing syndrome may occur with adrenal incidentalomas, subclinical Cushing syndrome is seen more commonly. Subclinical Cushing syndrome, now commonly referred to as “mild autonomous cortisol excess,” is characterized by ACTH-independent cortisol secretion that may result in metabolic (hyperglycemia and hypertension) and bone (osteoporosis) effects of hypercortisolism, but not the more specific clinical features of full Cushing syndrome, such as supraclavicular fat pads, wide violaceous striae (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_en_f04",
"wrapId":"14",
"children":[
"Figure 4"
]
}
]
},
")"
]
},
", facial plethora, and proximal muscle weakness. Initial testing for subclinical Cushing syndrome is achieved with an overnight LDST. A cortisol level less than 1.8 μg/dL (49.7 nmol/L) is considered a diagnostic criterion for the exclusion of autonomous secretion, and greater than 1.8 μg/dL (49.7 nmol/L) is evidence of a positive test. Following a positive result, further tests are required to confirm cortisol autonomy. These tests may include measurement of ACTH (suppressed), DHEA sulfate (low), 24-hour urine free cortisol, and an overnight 8-mg dexamethasone suppression test. The decision whether to proceed to adrenalectomy in subclinical Cushing syndrome is controversial; decision-making should be shared with an endocrinologist."
]
},
{
"type":"inline-wrap",
"wrapId":"14",
"contentIds":[
"mk19_b_en_f04"
]
},
{
"type":"p",
"hlId":"434ed1",
"children":[
"Imaging findings can help differentiate between a benign and a malignant adrenal mass (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t28",
"wrapId":"15",
"children":[
"Table 28"
]
}
]
},
")"
]
},
". Biopsy has a very limited role in evaluating incidentalomas and is reserved for lesions suspicious for metastases, lymphoma, or an infiltrative process, including some infections. If biopsy is pursued, pheochromocytoma should be ruled out with biochemical testing before biopsy to avoid the possibility of a hypertensive crisis. Biopsy should additionally not be performed when a primary adrenocortical carcinoma is suspected because tumor seeding is possible. If the adrenocortical carcinoma is suspected, the diagnosis should be established by adrenalectomy."
]
},
{
"type":"inline-wrap",
"wrapId":"15",
"contentIds":[
"mk19_b_en_t28"
]
},
{
"type":"p",
"hlId":"1677e7",
"children":[
"An algorithm for management of adrenal incidentaloma, including monitoring of lesions that do not require adrenalectomy, is shown in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_en_f08",
"wrapId":"16",
"children":[
"Figure 8"
]
}
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"16",
"contentIds":[
"mk19_b_en_f08"
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"738146",
"children":[
"All patients with adrenal incidentaloma should be evaluated for pheochromocytoma and hypercortisolism; those with hypertension should also be evaluated for primary aldosteronism."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s3_5",
"bibliography":true,
"title":{
"__html":"Bibliography"
},
"titleNode":{
"type":"section-title",
"hlId":"a7cc81",
"children":[
"Bibliography"
]
},
"children":[
{
"type":"references",
"children":[
{
"type":"reference",
"children":[
"Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and treatment of primary adrenal insufficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101:364-89. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/26760044",
"target":"_blank"
},
"children":[
"PMID: 26760044"
]
},
" doi:10.1210/jc.2015-1710"
]
},
{
"type":"reference",
"children":[
"Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2016;175:G1-G34. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27390021",
"target":"_blank"
},
"children":[
"PMID: 27390021"
]
},
" doi:10.1530/EJE-16-0467"
]
},
{
"type":"reference",
"children":[
"Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: dase detection, diagnosis, and treatment: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101:1889-916. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/26934393",
"target":"_blank"
},
"children":[
"PMID: 26934393"
]
},
" doi:10.1210/jc.2015-4061"
]
},
{
"type":"reference",
"children":[
"Lacroix A, Feelders RA, Stratakis CA, et al. Cushing's syndrome. Lancet. 2015;386:913-27. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/26004339",
"target":"_blank"
},
"children":[
"PMID: 26004339"
]
},
" doi:10.1016/S0140-6736(14)61375-1"
]
},
{
"type":"reference",
"children":[
"Lenders JW, Duh QY, Eisenhofer G, et al; Endocrine Society. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99:1915-42. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/24893135",
"target":"_blank"
},
"children":[
"PMID: 24893135"
]
},
" doi:10.1210/jc.2014-1498"
]
},
{
"type":"reference",
"children":[
"Libé R. Adrenocortical carcinoma (ACC): diagnosis, prognosis, and treatment. Front Cell Dev Biol. 2015;3:45. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/26191527",
"target":"_blank"
},
"children":[
"PMID: 26191527"
]
},
" doi:10.3389/fcell.2015.00045"
]
},
{
"type":"reference",
"children":[
"Rossi GP, Cesari M, Cuspidi C, et al. Long-term control of arterial hypertension and regression of left ventricular hypertrophy with treatment of primary aldosteronism. Hypertension. 2013;62:62-9. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/23648698",
"target":"_blank"
},
"children":[
"PMID: 23648698"
]
},
" doi:10.1161/HYPERTENSIONAHA.113.01316"
]
},
{
"type":"reference",
"children":[
"Rushworth RL, Torpy DJ, Falhammar H. Adrenal Crisis. N Engl J Med. 2019;381:852-861. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31461595",
"target":"_blank"
},
"children":[
"PMID: 31461595"
]
},
" doi:10.1056/NEJMra1807486"
]
}
]
}
]
}
]
},
"tablesContent":{
"mk19_b_en_t25":{
"id":"mk19_b_en_t25",
"number":25,
"bookId":"en",
"title":{
"__html":"Case Detection Indications for Primary Aldosteronism and Pheochromocytoma"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"8c5dc4",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 25. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t25"
}
]
},
"Case Detection Indications for Primary Aldosteronism and Pheochromocytoma"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"052f1d",
"class":"col hd l",
"children":[
"Primary Aldosteronism"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"252985",
"class":"cell txt l",
"children":[
"Untreated hypertension with sustained BP >150/100 mm Hg"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d2fd79",
"class":"cell txt l",
"children":[
"Resistant hypertension (>140/90 mm Hg) on three-drug therapy including a diuretic"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3257d3",
"class":"cell txt l",
"children":[
"Hypertension and an incidentally discovered adrenal mass"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fb4a2c",
"class":"cell txt l",
"children":[
"Hypertension associated with spontaneous or diuretic-induced hypokalemia"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"58d969",
"class":"cell txt l",
"children":[
"Hypertension in the setting of a first-degree relative with PA"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3fdbb9",
"class":"cell txt l",
"children":[
"Hypertension in the setting of family history of hypertension onset age <40 years"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"46f076",
"class":"col hd l",
"children":[
"Pheochromocytoma/Paraganglioma"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"499084",
"class":"cell txt l",
"children":[
"Adrenergic-type spells (headache, sweating, and tachycardia) with or without hypertension"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2d2186",
"class":"cell txt l",
"children":[
"Incidentally discovered adrenal mass with unenhanced CT >10 HU or without hypertension"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d2fd79",
"class":"cell txt l",
"children":[
"Resistant hypertension (>140/90 mm Hg) on three-drug therapy including a diuretic"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"30962f",
"class":"cell txt l",
"children":[
"Hypertension with onset age <20 years"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5e7394",
"class":"cell txt l",
"children":[
"Idiopathic cardiomyopathy"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2c240b",
"class":"cell txt l",
"children":[
"Hypertensive episode induced by anesthesia, surgery, or angiography"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a49a16",
"class":"cell txt l",
"children":[
"Paraganglioma"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"568e40",
"class":"cell txt l",
"children":[
"Familial syndromes that predispose to pheochromocytoma: VHL, SDHx mutation, NF-1, CSD, and MEN2"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5cf1d5",
"class":"cell txt l",
"children":[
"Family history of pheochromocytoma or paraganglioma"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"BP = blood pressure; CSD = Carney-Stratakis dyad; HU = Hounsfield units (measure of radiodensity compared with water); MEN2 = multiple endocrine neoplasia type 2; NF-1 = neurofibromatosis type 1; PA = primary aldosteronism; SDHx = succinate dehydrogenase; VHL = von Hippel-Lindau."
]
]
},
"mk19_b_en_t26":{
"id":"mk19_b_en_t26",
"number":26,
"bookId":"en",
"title":{
"__html":"Effect of Commonly Prescribed Medications on Measurements of Plasma Renin Activity and Plasma Aldosterone Concentration"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"1107de",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 26. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t26"
}
]
},
"Effect of Commonly Prescribed Medications on Measurements of Plasma Renin Activity and Plasma Aldosterone Concentration"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"714f6b",
"class":"col hd l",
"children":[
"Effect on Test Results"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e4d885",
"class":"col hd l",
"children":[
"Medication Class"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1bca05",
"class":"col hd c",
"children":[
"PRA"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"37e3b0",
"class":"col hd c",
"children":[
"PAC"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4cc35c",
"class":"col hd c",
"children":[
"PAC/PRA"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0b86fc",
"class":"cell txt l",
"children":[
"False-positive"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0113b9",
"class":"cell txt l",
"children":[
"α",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"-Adrenoceptor agonist"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b2b342",
"class":"cell txt c",
"children":[
"↓↓"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a014e2",
"class":"cell txt c",
"children":[
"↓"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fa1be6",
"class":"cell txt c",
"children":[
"↑"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ab102b",
"class":"cell txt l",
"children":[
"β-Adrenoceptor blocker"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b2b342",
"class":"cell txt c",
"children":[
"↓↓"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a014e2",
"class":"cell txt c",
"children":[
"↓"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fa1be6",
"class":"cell txt c",
"children":[
"↑"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1808d4",
"class":"cell txt l",
"children":[
"Direct renin inhibitor"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a014e2",
"class":"cell txt c",
"children":[
"↓"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a014e2",
"class":"cell txt c",
"children":[
"↓"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fa1be6",
"class":"cell txt c",
"children":[
"↑"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a6d3e1",
"class":"cell txt l",
"children":[
"NSAID"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b2b342",
"class":"cell txt c",
"children":[
"↓↓"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a014e2",
"class":"cell txt c",
"children":[
"↓"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fa1be6",
"class":"cell txt c",
"children":[
"↑"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"088c5c",
"class":"cell txt l",
"children":[
"False-negative"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"49006b",
"class":"cell txt l",
"children":[
"ACE inhibitor/ARB"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"19d010",
"class":"cell txt c",
"children":[
"↑↑"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a014e2",
"class":"cell txt c",
"children":[
"↓"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a014e2",
"class":"cell txt c",
"children":[
"↓"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"44347f",
"class":"cell txt l",
"children":[
"Dihydropyridine CCB"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fa1be6",
"class":"cell txt c",
"children":[
"↑"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a014e2",
"class":"cell txt c",
"children":[
"↓"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a014e2",
"class":"cell txt c",
"children":[
"↓"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"30f9d4",
"class":"cell txt l",
"children":[
"Diuretic",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"19d010",
"class":"cell txt c",
"children":[
"↑↑"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fa1be6",
"class":"cell txt c",
"children":[
"↑"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a014e2",
"class":"cell txt c",
"children":[
"↓"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"354f5b",
"class":"cell txt l",
"children":[
"Mineralocorticoid receptor antagonist"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"19d010",
"class":"cell txt c",
"children":[
"↑↑"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fa1be6",
"class":"cell txt c",
"children":[
"↑"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a014e2",
"class":"cell txt c",
"children":[
"↓"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b98a0f",
"class":"cell txt l",
"children":[
"SSRI"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt c",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fa1be6",
"class":"cell txt c",
"children":[
"↑"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a014e2",
"class":"cell txt c",
"children":[
"↓"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"ARB = angiotensin receptor blocker; CCB = calcium channel blocker; PAC = plasma aldosterone concentration; PRA = plasma renin activity; SSRI = selective serotonin reuptake inhibitor."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Both potassium-sparing (amiloride) and potassium-wasting (hydrochlorothiazide) diuretics."
]
]
},
"mk19_b_en_t27":{
"id":"mk19_b_en_t27",
"number":27,
"bookId":"en",
"title":{
"__html":"Substances Associated With False-Positive Biochemical Testing for Pheochromocytoma"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"2c9462",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 27. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t27"
}
]
},
"Substances Associated With False-Positive Biochemical Testing for Pheochromocytoma"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"572632",
"class":"col hd l",
"children":[
"Drug Class"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c69bcb",
"class":"col hd l",
"children":[
"Medication/Substance"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ec825e",
"class":"cell txt l",
"children":[
"Analgesics"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"07d079",
"class":"cell txt l",
"children":[
"Acetaminophen"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1ec16e",
"class":"cell txt l",
"children":[
"Antiemetics"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2a3897",
"class":"cell txt l",
"children":[
"Prochlorperazine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c7e7f0",
"class":"cell txt l",
"children":[
"Antihypertensives"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7cc545",
"class":"cell txt l",
"children":[
"Phenoxybenzamine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"414e8d",
"class":"cell txt l",
"children":[
"Psychiatric medications"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"de15a9",
"class":"cell txt l",
"children":[
"Antipsychotics"
]
},
" ",
{
"type":"p",
"hlId":"7229a4",
"class":"cell txt l",
"children":[
"Buspirone"
]
},
" ",
{
"type":"p",
"hlId":"2df6c1",
"class":"cell txt l",
"children":[
"Monoamine oxidase inhibitors"
]
},
" ",
{
"type":"p",
"hlId":"10320f",
"class":"cell txt l",
"children":[
"Serotonin norepinephrine reuptake inhibitors"
]
},
" ",
{
"type":"p",
"hlId":"2ae55a",
"class":"cell txt l",
"children":[
"Tricyclic antidepressants"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a3320b",
"class":"cell txt l",
"children":[
"Stimulants"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"91b212",
"class":"cell txt l",
"children":[
"Amphetamines"
]
},
" ",
{
"type":"p",
"hlId":"c6cafa",
"class":"cell txt l",
"children":[
"Methylphenidate"
]
},
" ",
{
"type":"p",
"hlId":"0a1541",
"class":"cell txt l",
"children":[
"Cocaine"
]
},
" ",
{
"type":"p",
"hlId":"17e78a",
"class":"cell txt l",
"children":[
"Caffeine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2c055d",
"class":"cell txt l",
"children":[
"Other agents"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fed966",
"class":"cell txt l",
"children":[
"Levodopa"
]
},
" ",
{
"type":"p",
"hlId":"baf623",
"class":"cell txt l",
"children":[
"Decongestants (pseudoephedrine)"
]
},
" ",
{
"type":"p",
"hlId":"a8d7cb",
"class":"cell txt l",
"children":[
"Reserpine"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ab85d9",
"class":"cell txt l",
"children":[
"Withdrawal"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"74accf",
"class":"cell txt l",
"children":[
"Clonidine"
]
},
" ",
{
"type":"p",
"hlId":"927377",
"class":"cell txt l",
"children":[
"Ethanol"
]
},
" ",
{
"type":"p",
"hlId":"0ead3c",
"class":"cell txt l",
"children":[
"Illicit drugs"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[

]
},
"mk19_b_en_t28":{
"id":"mk19_b_en_t28",
"number":28,
"bookId":"en",
"title":{
"__html":"Typical Imaging Characteristics of Adrenal Masses"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"5521e0",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 28. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t28"
}
]
},
"Typical Imaging Characteristics of Adrenal Masses"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"476021",
"class":"col hd l",
"children":[
"Adrenal Mass"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9c831a",
"class":"col hd l",
"children":[
"Overall"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"112c61",
"class":"col hd l",
"children":[
"CT"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e7ee03",
"class":"col hd l",
"children":[
"MRI Signal Intensity",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b7ca7e",
"class":"cell txt l",
"children":[
"Adrenal adenoma"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"da7b76",
"class":"cell txt l",
"children":[
"Diameter <4 cm"
]
},
" ",
{
"type":"p",
"hlId":"9fe854",
"class":"cell txt l",
"children":[
"Homogeneous enhancement",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" ",
{
"type":"p",
"hlId":"699ed5",
"class":"cell txt l",
"children":[
"Round, regular margins"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"52a0ea",
"class":"cell txt l",
"children":[
"Density ≤10 HU"
]
},
" ",
{
"type":"p",
"hlId":"69c69c",
"class":"cell txt l",
"children":[
"Contrast washout >50% (10 min)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f35e25",
"class":"cell txt l",
"children":[
"Isointense on T2-weighted images"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c5c824",
"class":"cell txt l",
"children":[
"Adrenocortical carcinoma"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d84324",
"class":"cell txt l",
"children":[
"Usually >4 cm"
]
},
" ",
{
"type":"p",
"hlId":"75df2f",
"class":"cell txt l",
"children":[
"Heterogeneous enhancement",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" ",
{
"type":"p",
"hlId":"59950c",
"class":"cell txt l",
"children":[
"Irregular margins"
]
},
" ",
{
"type":"p",
"hlId":"cc1daa",
"class":"cell txt l",
"children":[
"Calcifications, necrosis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93a98e",
"class":"cell txt l",
"children":[
"Density >10 HU"
]
},
" ",
{
"type":"p",
"hlId":"b63ec1",
"class":"cell txt l",
"children":[
"Contrast washout <50% (10 min)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e76377",
"class":"cell txt l",
"children":[
"Hyperintense on T2-weighted images"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"43d333",
"class":"cell txt l",
"children":[
"Pheochromocytoma"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fbb6c5",
"class":"cell txt l",
"children":[
"Variable size; average 4 cm in symptomatic patients"
]
},
" ",
{
"type":"p",
"hlId":"6e2112",
"class":"cell txt l",
"children":[
"Heterogeneous enhancement",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
", cystic areas"
]
},
" ",
{
"type":"p",
"hlId":"699ed5",
"class":"cell txt l",
"children":[
"Round, regular margins"
]
},
" ",
{
"type":"p",
"hlId":"6ebff7",
"class":"cell txt l",
"children":[
"Can be bilateral"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2da101",
"class":"cell txt l",
"children":[
"Density >10 HU (usually >30)"
]
},
" ",
{
"type":"p",
"hlId":"b52bd7",
"class":"cell txt l",
"children":[
"Contrast washout"
]
},
" ",
{
"type":"p",
"hlId":"004a59",
"class":"cell txt l",
"children":[
"<50% (10 min)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e76377",
"class":"cell txt l",
"children":[
"Hyperintense on T2-weighted images"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"91fb57",
"class":"cell txt l",
"children":[
"Metastases"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"443966",
"class":"cell txt l",
"children":[
"Variable margins"
]
},
" ",
{
"type":"p",
"hlId":"6ebff7",
"class":"cell txt l",
"children":[
"Can be bilateral"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93a98e",
"class":"cell txt l",
"children":[
"Density >10 HU"
]
},
" ",
{
"type":"p",
"hlId":"b63ec1",
"class":"cell txt l",
"children":[
"Contrast washout <50% (10 min)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e76377",
"class":"cell txt l",
"children":[
"Hyperintense on T2-weighted images"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"HU = Hounsfield units (measure of radiodensity compared with water)."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Signal intensity as compared with liver."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Enhancement following intravenous contrast administration."
]
]
},
"mk19_b_en_t29":{
"id":"mk19_b_en_t29",
"number":29,
"bookId":"en",
"title":{
"__html":"Multiple Endocrine Neoplasia Syndromes"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"e1c15e",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 29. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t29"
}
]
},
"Multiple Endocrine Neoplasia Syndromes"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a1fa27",
"class":"col hd l",
"children":[
"Type"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"590163",
"class":"col hd l",
"children":[
"Mutation"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"87ec11",
"class":"col hd l",
"children":[
"Most Common Feature"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dbd42a",
"class":"col hd l",
"children":[
"Associated Features"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c4ca42",
"class":"cell txt l",
"children":[
"1"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"31f4ba",
"class":"cell txt l",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"MEN1"
]
},
" (tumor suppressor gene)"
]
},
" ",
{
"type":"p",
"hlId":"869926",
"class":"cell txt l",
"children":[
"(inheritance of one mutated allele with somatic mutation in other allele leads to neoplasia)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1bd5dd",
"class":"cell txt l",
"children":[
"Parathyroid hyperplasia (often multiple)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"064ecf",
"class":"cell txt l",
"children":[
"Pancreatic islet cell and enteric neuroendocrine tumors (gastrinoma, insulinoma most common)"
]
},
" ",
{
"type":"p",
"hlId":"d7e5ae",
"class":"cell txt l",
"children":[
"Pituitary adenoma"
]
},
" ",
{
"type":"p",
"hlId":"312dc7",
"class":"cell txt l",
"children":[
"Adrenocortical adenoma"
]
},
" ",
{
"type":"p",
"hlId":"d1b61e",
"class":"cell txt l",
"children":[
"Skin lesions: collagenomas, angiofibromas"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5f5468",
"class":"cell txt l",
"children":[
"2A"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"29186e",
"class":"cell txt l",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"RET"
]
},
" (proto-oncogene)"
]
},
" ",
{
"type":"p",
"hlId":"d72da2",
"class":"cell txt l",
"children":[
"(exon 11, codon 634",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
")"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b86c83",
"class":"cell txt l",
"children":[
"Medullary thyroid carcinoma"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"66fcc3",
"class":"cell txt l",
"children":[
"Pheochromocytoma (often multifocal)"
]
},
" ",
{
"type":"p",
"hlId":"9dc879",
"class":"cell txt l",
"children":[
"Parathyroid hyperplasia"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"49ba75",
"class":"cell txt l",
"children":[
"2B"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"29186e",
"class":"cell txt l",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"RET"
]
},
" (proto-oncogene)"
]
},
" ",
{
"type":"p",
"hlId":"848f9b",
"class":"cell txt l",
"children":[
"(exon 16, codon 918",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
")"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b86c83",
"class":"cell txt l",
"children":[
"Medullary thyroid carcinoma"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"66fcc3",
"class":"cell txt l",
"children":[
"Pheochromocytoma (often multifocal)"
]
},
" ",
{
"type":"p",
"hlId":"f140af",
"class":"cell txt l",
"children":[
"Mucosal neuroma (characteristic)"
]
},
" ",
{
"type":"p",
"hlId":"fb83a2",
"class":"cell txt l",
"children":[
"Gastrointestinal ganglioneuroma"
]
},
" ",
{
"type":"p",
"hlId":"1c26da",
"class":"cell txt l",
"children":[
"Marfanoid body habitus"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Most common mutation observed."
]
]
},
"mk19_b_en_t30":{
"id":"mk19_b_en_t30",
"number":30,
"bookId":"en",
"title":{
"__html":"Clinical and Laboratory Manifestations of Primary Adrenal Failure"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a3c5c6",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 30. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t30"
}
]
},
"Clinical and Laboratory Manifestations of Primary Adrenal Failure"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"081016",
"class":"col hd l",
"children":[
"Hormone Deficiency"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dd2968",
"class":"col hd l",
"children":[
"Symptoms"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4713b5",
"class":"col hd l",
"children":[
"Signs"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"95eaef",
"class":"col hd l",
"children":[
"Laboratory Findings"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a10038",
"class":"cell txt l",
"children":[
"Cortisol"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b5ff1b",
"class":"cell txt l",
"children":[
"Fatigue"
]
},
" ",
{
"type":"p",
"hlId":"bc1d14",
"class":"cell txt l",
"children":[
"Weakness"
]
},
" ",
{
"type":"p",
"hlId":"887acf",
"class":"cell txt l",
"children":[
"Low-grade fever"
]
},
" ",
{
"type":"p",
"hlId":"8cd84a",
"class":"cell txt l",
"children":[
"Weight loss"
]
},
" ",
{
"type":"p",
"hlId":"b11759",
"class":"cell txt l",
"children":[
"Anorexia"
]
},
" ",
{
"type":"p",
"hlId":"c7bca5",
"class":"cell txt l",
"children":[
"Nausea/vomiting"
]
},
" ",
{
"type":"p",
"hlId":"eb7523",
"class":"cell txt l",
"children":[
"Abdominal pain"
]
},
" ",
{
"type":"p",
"hlId":"b0bd5d",
"class":"cell txt l",
"children":[
"Arthralgia"
]
},
" ",
{
"type":"p",
"hlId":"46dc35",
"class":"cell txt l",
"children":[
"Myalgia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"18e2d6",
"class":"cell txt l",
"children":[
"Hyperpigmentation",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
" (palmar creases, extensor surfaces, buccal mucosa)"
]
},
" ",
{
"type":"p",
"hlId":"b80f60",
"class":"cell txt l",
"children":[
{
"type":"table-inline-figure",
"target":"mk19_b_en_f30",
"children":[
"Figure 30"
]
}
]
},
" ",
{
"type":"p",
"hlId":"a10d58",
"class":"cell txt l",
"children":[
"Orthostasis"
]
},
" ",
{
"type":"p",
"hlId":"2a9afd",
"class":"cell txt l",
"children":[
"Hypotension"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7386eb",
"class":"cell txt l",
"children":[
"↓ Serum cortisol"
]
},
" ",
{
"type":"p",
"hlId":"a82a8a",
"class":"cell txt l",
"children":[
"↑ Serum ACTH"
]
},
" ",
{
"type":"p",
"hlId":"2404f2",
"class":"cell txt l",
"children":[
"↓ Serum sodium",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" ",
{
"type":"p",
"hlId":"e6706c",
"class":"cell txt l",
"children":[
"↓ Plasma glucose",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b32476",
"class":"cell txt l",
"children":[
"Aldosterone"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"28dd55",
"class":"cell txt l",
"children":[
"Salt craving"
]
},
" ",
{
"type":"p",
"hlId":"cb28b7",
"class":"cell txt l",
"children":[
"Dizziness"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a10d58",
"class":"cell txt l",
"children":[
"Orthostasis"
]
},
" ",
{
"type":"p",
"hlId":"2a9afd",
"class":"cell txt l",
"children":[
"Hypotension"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"89b8b9",
"class":"cell txt l",
"children":[
"↑ PRA"
]
},
" ",
{
"type":"p",
"hlId":"11955a",
"class":"cell txt l",
"children":[
"↓ Serum sodium"
]
},
" ",
{
"type":"p",
"hlId":"6059ea",
"class":"cell txt l",
"children":[
"↑ Serum potassium"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bd650f",
"class":"cell txt l",
"children":[
"DHEAS"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bc132c",
"class":"cell txt l",
"children":[
"Reduced libido",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"637601",
"class":"cell txt l",
"children":[
"Decreased axillary or pubic hair",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"218ff8",
"class":"cell txt l",
"children":[
"↓ Serum DHEAS"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"ACTH = adrenocorticotropic hormone; DHEAS = dehydroepiandrosterone sulfate; PRA = plasma renin activity."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Occurs exclusively in primary adrenal failure."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Cortisol inhibits secretion of antidiuretic hormone (ADH), so hypocortisolemia leads to increased secretion of ADH and hyponatremia."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
"Rare in adults."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
},
"Women only."
]
]
},
"mk19_b_en_t31":{
"id":"mk19_b_en_t31",
"number":31,
"bookId":"en",
"title":{
"__html":"Dose Equivalence and Relative Potencies of Common Synthetic Oral Glucocorticoids"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"21f8f6",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 31. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t31"
}
]
},
"Dose Equivalence and Relative Potencies of Common Synthetic Oral Glucocorticoids"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0b68c9",
"class":"col hd l",
"children":[
"Synthetic Glucocorticoid"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2da7c6",
"class":"col hd l",
"children":[
"Equivalent Dose (mg)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bb75dc",
"class":"col hd l",
"children":[
"Biologic Half-Life (h)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"edc063",
"class":"col hd l",
"children":[
"Relative Anti-Inflammatory Potency",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7b37a3",
"class":"col hd l",
"children":[
"Relative Mineralocorticoid Potency",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"071ea7",
"class":"cell txt l",
"children":[
"Hydrocortisone"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"98f137",
"class":"cell txt l",
"children":[
"20"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b049a0",
"class":"cell txt l",
"children":[
"8-12"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c4ca42",
"class":"cell txt l",
"children":[
"1"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7c4cdc",
"class":"cell txt l",
"children":[
"1/125"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f70f42",
"class":"cell txt l",
"children":[
"Prednisolone/ prednisone"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e4da3b",
"class":"cell txt l",
"children":[
"5"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b7deee",
"class":"cell txt l",
"children":[
"18-36"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a87ff6",
"class":"cell txt l",
"children":[
"4"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e967dd",
"class":"cell txt l",
"children":[
"1/150"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3a8f74",
"class":"cell txt l",
"children":[
"Methylprednisolone"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a87ff6",
"class":"cell txt l",
"children":[
"4"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b7deee",
"class":"cell txt l",
"children":[
"18-36"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e4da3b",
"class":"cell txt l",
"children":[
"5"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cfcd20",
"class":"cell txt l",
"children":[
"0"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"81150f",
"class":"cell txt l",
"children":[
"Dexamethasone"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4c8d9a",
"class":"cell txt l",
"children":[
"0.75"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0c3657",
"class":"cell txt l",
"children":[
"36-54"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f5877e",
"class":"cell txt l",
"children":[
"25-50"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cfcd20",
"class":"cell txt l",
"children":[
"0"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Anti-inflammatory potency relative to hydrocortisone."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Mineralocorticoid potency relative to fludrocortisone."
]
]
},
"mk19_b_en_t32":{
"id":"mk19_b_en_t32",
"number":32,
"bookId":"en",
"title":{
"__html":"Chronic Medical Treatment of Primary Adrenal Failure"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"de0a27",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 32. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t32"
}
]
},
"Chronic Medical Treatment of Primary Adrenal Failure"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"353bd6",
"class":"col hd l",
"children":[
"Medication"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7560d4",
"class":"col hd l",
"children":[
"Basal Dose"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ea61e2",
"class":"col hd l",
"children":[
"Considerations"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f10e78",
"class":"cell txt l",
"children":[
"Glucocorticoid",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5f3d27",
"class":"cell txt l",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"“Sick day rules”"
]
},
": Patient follows at home."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"071ea7",
"class":"cell txt li",
"children":[
"Hydrocortisone"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ff2ce2",
"class":"cell txt l",
"children":[
"Usually 15-25 mg/d, divided into 2-3 doses (with largest dose administered in the morning)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7179d3",
"class":"cell txt l",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"For minor physiologic stress (upper respiratory infection, fever, minor surgery under local anesthesia)"
]
},
": 2-3 times basal dose for 2-3 days"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0c03f2",
"class":"cell txt li",
"children":[
"Prednisone"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"183734",
"class":"cell txt l",
"children":[
"4-5 mg once daily"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5f7cb0",
"class":"cell txt l",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Stress dosing"
]
},
": Health care providers follow while patient is in the hospital."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e05274",
"class":"cell txt l",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"How to dose:"
]
},
" Titrate to clinical response with goal of no signs or symptoms of cortisol deficiency or excess (increase dose if symptoms of cortisol deficiency remain; decrease if CS signs and symptoms are present)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"811844",
"class":"cell txt l",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"For moderate physiologic stress (minor or moderate surgery with general anesthesia)"
]
},
": Hydrocortisone 25-75 mg/d orally or IV for 1-2 days"
]
},
" ",
{
"type":"p",
"hlId":"7683a8",
"class":"cell txt l",
"children":[
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"For major physiologic stress (major surgery, trauma, critical illness, or childbirth)"
]
},
": Hydrocortisone 100 mg IV followed by 50 mg every 6 h IV; rapid tapering and switch to oral regimen depending on clinical state"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"281aa1",
"class":"cell txt l",
"children":[
"Mineralocorticoid"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d7eb11",
"class":"cell txt li",
"children":[
"Fludrocortisone"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cd34bc",
"class":"cell txt l",
"children":[
"0.05-0.2 mg once daily in morning"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8d617f",
"class":"cell txt l",
"children":[
"Fludrocortisone is not required if hydrocortisone dose is >40 mg/d."
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2ec584",
"class":"cell txt l",
"children":[
"How to dose:"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c94697",
"class":"cell txt li",
"children":[
"Titrate to:"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt li",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt li",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9e8075",
"class":"cell txt li",
"children":[
"1. Normal BP"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt li",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt li",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e11803",
"class":"cell txt li",
"children":[
"2. Normal serum Na, K"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt li",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ba1181",
"class":"cell txt l",
"children":[
"Adrenal androgen"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"16f5ec",
"class":"cell txt li",
"children":[
"DHEA"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2a19ef",
"class":"cell txt l",
"children":[
"25-50 mg once daily, can titrate upwards"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"83c5fd",
"class":"cell txt l",
"children":[
"Consider DHEA for women with impaired mood or sense of well-being when glucocorticoid replacement has been optimized."
]
},
" ",
{
"type":"p",
"hlId":"04506e",
"class":"cell txt l",
"children":[
"DHEA replacement is controversial and robust data to demonstrate benefit are lacking."
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"BP = blood pressure; CS = Cushing syndrome; DHEA = dehydroepiandrosterone; IV = intravenous; Na = sodium; K = potassium."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Shorter-acting glucocorticoids are preferred over longer-acting agents owing to a lower risk of glucocorticoid excess. Longer-acting preparations have the advantage of once-daily dosing."
]
]
}
}
}